(HAE) Haemonetics - Overview
Stock: Plasma, Hemostasis, Guidewire, Closure, Autotransfusion
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 40.6% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -19.75 |
| Character TTM | |
|---|---|
| Beta | 0.619 |
| Beta Downside | 0.159 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.04% |
| CAGR/Max DD | -0.22 |
Description: HAE Haemonetics January 11, 2026
Haemonetics (NYSE:HAE) is a Boston-based medical-technology firm that sells a broad portfolio of blood-management and procedural-guidance solutions to hospitals worldwide, ranging from automated plasmapheresis systems (NexSys PCS/PCS2) and donor-management software (NexLynk DMS, Donor360) to hemostasis analyzers (TEG, HAS) and catheter-based vascular closure devices (VASCADE).
The company’s revenue is heavily tied to the growth of the plasma-collection market, which analysts estimate will expand at ~5% CAGR through 2028 driven by rising demand for plasma-derived therapeutics and tighter FDA regulations that favor automated, traceable collection processes. In FY2023 Haemonetics reported $1.18 billion in revenue, with a 9% year-over-year increase in the Plasma Collection segment and an operating margin of roughly 12%.
Key economic drivers include aging demographics that increase surgical volume (orthopedic, cardiac, trauma) and the shift toward value-based care, which pushes hospitals to adopt blood-conservation technologies such as Cell Saver Elite + and the VASCADE closure platform. Additionally, the company benefits from recurring software-as-a-service revenue streams tied to its Donor360 and TEG Manager platforms, which have shown double-digit subscription growth in the past two years.
Haemonetics distributes its products through a mix of direct sales teams, independent distributors, and clinical specialists, allowing it to maintain high-touch relationships in niche hospital settings while scaling its software offerings globally.
For a deeper quantitative view, see the ValueRay analyst dashboard.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 175.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 8.58 > 1.0 |
| NWC/Revenue: 30.63% < 20% (prev 54.80%; Δ -24.16% < -1%) |
| CFO/TA 0.14 > 3% & CFO 338.8m > Net Income 175.4m |
| Net Debt (861.4m) to EBITDA (375.5m): 2.29 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.0m) vs 12m ago -7.21% < -2% |
| Gross Margin: 59.32% > 18% (prev 0.55%; Δ 5877 % > 0.5%) |
| Asset Turnover: 52.50% > 50% (prev 54.26%; Δ -1.76% > 0%) |
| Interest Coverage Ratio: 13.14 > 6 (EBITDA TTM 375.5m / Interest Expense TTM 20.0m) |
Altman Z'' 2.50
| A: 0.16 (Total Current Assets 943.7m - Total Current Liabilities 539.9m) / Total Assets 2.49b |
| B: 0.15 (Retained Earnings 381.1m / Total Assets 2.49b) |
| C: 0.10 (EBIT TTM 262.9m / Avg Total Assets 2.51b) |
| D: 0.22 (Book Value of Equity 346.9m / Total Liabilities 1.58b) |
| Altman-Z'' Score: 2.50 = A |
Beneish M -3.20
| DSRI: 0.96 (Receivables 195.7m/211.9m, Revenue 1.32b/1.37b) |
| GMI: 0.93 (GM 59.32% / 55.29%) |
| AQI: 1.02 (AQ_t 0.50 / AQ_t-1 0.49) |
| SGI: 0.96 (Revenue 1.32b / 1.37b) |
| TATA: -0.07 (NI 175.4m - CFO 338.8m) / TA 2.49b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of HAE shares?
Over the past week, the price has changed by -12.30%, over one month by -29.67%, over three months by -18.15% and over the past year by -4.86%.
Is HAE a buy, sell or hold?
- StrongBuy: 3
- Buy: 5
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HAE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88 | 52.5% |
| Analysts Target Price | 88 | 52.5% |
| ValueRay Target Price | 57.1 | -1% |
HAE Fundamental Data Overview February 08, 2026
P/E Forward = 11.9332
P/S = 2.1071
P/B = 3.3151
P/EG = 0.9942
Revenue TTM = 1.32b USD
EBIT TTM = 262.9m USD
EBITDA TTM = 375.5m USD
Long Term Debt = 921.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 304.7m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 861.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.64b USD (2.78b + Debt 1.22b - CCE 363.4m)
Interest Coverage Ratio = 13.14 (Ebit TTM 262.9m / Interest Expense TTM 20.0m)
EV/FCF = 11.81x (Enterprise Value 3.64b / FCF TTM 308.1m)
FCF Yield = 8.47% (FCF TTM 308.1m / Enterprise Value 3.64b)
FCF Margin = 23.37% (FCF TTM 308.1m / Revenue TTM 1.32b)
Net Margin = 13.31% (Net Income TTM 175.4m / Revenue TTM 1.32b)
Gross Margin = 59.32% ((Revenue TTM 1.32b - Cost of Revenue TTM 536.2m) / Revenue TTM)
Gross Margin QoQ = 59.71% (prev 59.50%)
Tobins Q-Ratio = 1.46 (Enterprise Value 3.64b / Total Assets 2.49b)
Interest Expense / Debt = 0.66% (Interest Expense 8.12m / Debt 1.22b)
Taxrate = 25.40% (15.2m / 60.0m)
NOPAT = 196.1m (EBIT 262.9m * (1 - 25.40%))
Current Ratio = 1.75 (Total Current Assets 943.7m / Total Current Liabilities 539.9m)
Debt / Equity = 1.34 (Debt 1.22b / totalStockholderEquity, last quarter 911.5m)
Debt / EBITDA = 2.29 (Net Debt 861.4m / EBITDA 375.5m)
Debt / FCF = 2.80 (Net Debt 861.4m / FCF TTM 308.1m)
Total Stockholder Equity = 865.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.99% (Net Income 175.4m / Total Assets 2.49b)
RoE = 20.26% (Net Income TTM 175.4m / Total Stockholder Equity 865.9m)
RoCE = 14.71% (EBIT 262.9m / Capital Employed (Equity 865.9m + L.T.Debt 921.2m))
RoIC = 9.45% (NOPAT 196.1m / Invested Capital 2.08b)
WACC = 5.84% (E(2.78b)/V(4.00b) * Re(8.19%) + D(1.22b)/V(4.00b) * Rd(0.66%) * (1-Tc(0.25)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.43%
[DCF Debug] Terminal Value 88.43% ; FCFF base≈223.2m ; Y1≈275.4m ; Y5≈468.9m
Fair Price DCF = 275.3 (EV 13.66b - Net Debt 861.4m = Equity 12.79b / Shares 46.5m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 79.57 | EPS CAGR: 20.55% | SUE: 0.62 | # QB: 0
Revenue Correlation: 78.99 | Revenue CAGR: 6.78% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.17 | Chg30d=-0.062 | Revisions Net=-1 | Analysts=9
EPS next Year (2027-03-31): EPS=5.32 | Chg30d=-0.152 | Revisions Net=-1 | Growth EPS=+7.6% | Growth Revenue=+5.2%